X-ray crystal structures of an orally available aminopeptidase inhibitor, Tosedostat, bound to anti-malarial drug targets PfA-M1 and PfA-M17.
Drinkwater, N., Bamert, R.S., Sivaraman, K.K., Paiardini, A., McGowan, S.(2015) Proteins 83: 789-795
- PubMed: 25645579 
- DOI: https://doi.org/10.1002/prot.24771
- Primary Citation of Related Structures:  
4X2T, 4X2U - PubMed Abstract: 
New anti-malarial treatments are desperately required to face the spread of drug resistant parasites. Inhibition of metalloaminopeptidases, PfA-M1 and PfA-M17, is a validated therapeutic strategy for treatment of Plasmodium falciparum malaria. Here, we describe the crystal structures of PfA-M1 and PfA-M17 bound to chemotherapeutic agent Tosedostat. The inhibitor occupies the enzymes' putative product egress channels in addition to the substrate binding pockets; however, adopts different binding poses when bound to PfA-M1 and PfA-M17. These findings will be valuable for the continued development of selective inhibitors of PfA-M1 and PfA-M17.
Organizational Affiliation: 
Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, 3800, Australia.